Payment overview · 2025
General Payments
$677.17
39 reported records · 10 companies
Healthcare provider profile · identity verified
Cameron Don Bonds, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHEFFIELD, AL · NPI 1699205989
Verified facts
What the public records show
CMS Open Payments records show Cameron Don Bonds, MD received $677.17 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Nurtec Odt, Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $339.50 | 50.1% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.64 | 9.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.13 | 5.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.75 | 5.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.35 | 5.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.90 | 5.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.46 | 4.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.23 | 4.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.11 | 4.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.10 | 4.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $677.17 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $263.49 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $60.86 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $33.46 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.11 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.11 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 128 |
| Gabapentin | Gabapentin | 349 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 321 | 111 |
| Lisinopril | Lisinopril | 312 | 108 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 303 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 98 |
| Losartan Potassium | Losartan Potassium | 245 | 85 |
| Meloxicam | Meloxicam | 226 | 81 |
| Montelukast Sodium | Montelukast Sodium | 212 | 66 |
| Omeprazole | Omeprazole | 212 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 74 |
| Trazodone Hcl | Trazodone Hcl | 171 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 54 |
| Potassium Chloride | Potassium Chloride | 153 | 56 |
| Carvedilol | Carvedilol | 148 | 48 |
| Metformin Hcl | Metformin Hcl | 145 | 58 |
| Furosemide | Furosemide | 134 | 62 |
| Simvastatin | Simvastatin | 116 | 43 |
| Famotidine | Famotidine | 115 | 45 |
| Donepezil Hcl | Donepezil Hcl | 108 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 30 |
| Alprazolam | Alprazolam | 99 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 30 |
| Spironolactone | Spironolactone | 90 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 23 |
| Clonazepam | Clonazepam | 81 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 26 |
| Metformin Hcl Er | Metformin Hcl | 79 | 31 |
| Tramadol Hcl | Tramadol Hcl | 79 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 28 |
| Jardiance | Empagliflozin | 75 | 18 |
| Pregabalin | Pregabalin | 75 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 34 |
| Ezetimibe | Ezetimibe | 73 | 25 |
| Azithromycin | Azithromycin | 72 | 67 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 27 |
| Memantine Hcl | Memantine Hcl | 66 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 20 |
| Farxiga | Dapagliflozin Propanediol | 65 | 20 |
| Bupropion Xl | Bupropion Hcl | 64 | 28 |
| Buspirone Hcl | Buspirone Hcl | 64 | 34 |
| Eliquis | Apixaban | 63 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 21 |
| Prednisone | Prednisone | 61 | 46 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 27 |
| Ozempic | Semaglutide | 56 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 18 |
| Synthroid | Levothyroxine Sodium | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 15 |
| Sertraline Hcl | Sertraline Hcl | 54 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 21 |
| Mirtazapine | Mirtazapine | 52 | 17 |
| Allopurinol | Allopurinol | 51 | 18 |
| Chlorthalidone | Chlorthalidone | 51 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 20 |
| Celecoxib | Celecoxib | 47 | 17 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 18 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 11 |
| Diazepam | Diazepam | 39 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Eszopiclone | Eszopiclone | 39 | 13 |
| Fluconazole | Fluconazole | 39 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 17 |
| Ondansetron Odt | Ondansetron | 37 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 13 |
| Linzess | Linaclotide | 35 | 12 |
| Ketoconazole | Ketoconazole | 33 | 24 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 18 |
| Finasteride | Finasteride | 29 | 13 |
| Lorazepam | Lorazepam | 29 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Torsemide | Torsemide | 27 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Primidone | Primidone | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 11 |
| Atenolol | Atenolol | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Mounjaro | Tirzepatide | 21 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Nystatin | Nystatin | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 14 |
| Fluvastatin Sodium | Fluvastatin Sodium | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $677.17 · 39 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, Korlym, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error